Weekly update|Companies|Recruiting|Promote|Post a job

Vaxxinity

Founded: 2014

Location: Dallas, TX

Employee range: 50 - 200

Clinical stage: Clin3

Therapy area: COVID-19

Drug types: NEU, VAC, INF, CVV

Lead product: UB-612

Product link: https://vaxxinity.com/our-pipeline/

Funding: $85M IPO Nov 2021

vaxxinity.com

linkedin.com

job board

Short description:

Endobody Vaccines, Synthetic Peptides Vaccine

Drug notes:

UB-311 Clin2 Alzheimer's; UB-312 Clin1 Parkinson's, DLB, MSA; UB-313 Clin1 migraine; VXX-401 Clin1 hypercholesterolemia; undisclosed RD/Clin0 Alzheimer's, undisclosed

Long description:

Vaxxinity is a pioneering biotechnology company dedicated to advancing vaccine development through innovative scientific approaches. Leveraging state-of-the-art molecular biology and immunology techniques, Vaxxinity focuses on designing next-generation vaccines that target chronic diseases, which are currently expensive treatments with less than 1% of the global population. Their scientific endeavors emphasize the use of novel antigen design, adjuvant technologies, and vaccine delivery systems to enhance efficacy, safety, and scalability. With a commitment to rigorous research and clinical validation, Vaxxinity aims to contribute significantly to public health by addressing current and emerging infectious and chronic threats with affordable treatments.

Jobs:

Main

Contact: recruit@workinbiotech.com